Skip to main content
Erschienen in: Rheumatology International 8/2015

01.08.2015 | Original Article - Observational Research

Risk factors for subclinical inflammation in children with Familial Mediterranean fever

verfasst von: Meral Torun Bayram, Tufan Çankaya, Elçin Bora, Salih Kavukçu, Ayfer Ülgenalp, Alper Soylu, Mehmet Türkmen

Erschienen in: Rheumatology International | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Familial Mediterranean fever (FMF) is the most common autosomal recessive inherited inflammatory disease characterized by attacks of painful inflammation. Some patients with FMF have subclinical inflammation persisting between the attacks. We aimed to identify the demographic, clinical and genetic risk factors for subclinical inflammation in children with FMF. The medical records of the children with FMF were evaluated retrospectively for acute-phase response along with gender, age at the onset of symptoms and at the time of diagnosis, clinical signs and symptoms, the presence of amyloidosis and MEFV genotype. Patients with persistently elevated acute-phase response between the attacks were considered to have subclinical inflammation. Patients with or without subclinical inflammation (Group 1 and Group 2, respectively) were compared for the parameters defined above. Independent risk factors for subclinical inflammation were identified by multivariate logistic regression analysis. There were 105 children (male/female: 52/53) who were compliant on colchicine treatment. Subclinical inflammation was detected in 22 (20 %) patients. Group 1 had significantly higher rate of myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation compared with Group 2. However, only the presence of myalgia and erysipelas like erythema were found to be independent risk factors for subclinical inflammation (OR 9.8 and 5.9, respectively). Children with FMF who have myalgia and erysipelas like erythema during the attacks are particularly at risk of ongoing inflammation and should be closely monitored for subclinical inflammation even during attack-free periods.
Literatur
1.
Zurück zum Zitat Ozturk C, Halıcıoğlu O, Coker I, Gulez N, Sutçuoğlu S, Karaca N, Aksu G, Kutukcular N (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493–501PubMedCrossRef Ozturk C, Halıcıoğlu O, Coker I, Gulez N, Sutçuoğlu S, Karaca N, Aksu G, Kutukcular N (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493–501PubMedCrossRef
2.
Zurück zum Zitat Ozçakar ZB, Yalçinkaya F, Yüksel S, Acar B, Gökmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149–152PubMedCrossRef Ozçakar ZB, Yalçinkaya F, Yüksel S, Acar B, Gökmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149–152PubMedCrossRef
3.
Zurück zum Zitat The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRef The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRef
4.
Zurück zum Zitat Padeh S, Berkun Y (2007) Auto-inflammatory fever syndromes. Rheum Dis Clin N Am 33:585–623CrossRef Padeh S, Berkun Y (2007) Auto-inflammatory fever syndromes. Rheum Dis Clin N Am 33:585–623CrossRef
5.
Zurück zum Zitat Saatçi U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S (1997) Familial Mediterranean Fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619–623PubMedCrossRef Saatçi U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S (1997) Familial Mediterranean Fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619–623PubMedCrossRef
7.
Zurück zum Zitat Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415PubMedCrossRef Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415PubMedCrossRef
9.
Zurück zum Zitat Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1876–1885CrossRef Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1876–1885CrossRef
10.
Zurück zum Zitat Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30(2):138–143PubMedCrossRef Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30(2):138–143PubMedCrossRef
11.
Zurück zum Zitat Tchernitchko D, Legendre M, Delahaye A, Cazeneuve C, Niel F, Goossens M, Amselem S, Girodon E (2003) Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clin Chem 49:1942–1945PubMedCrossRef Tchernitchko D, Legendre M, Delahaye A, Cazeneuve C, Niel F, Goossens M, Amselem S, Girodon E (2003) Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clin Chem 49:1942–1945PubMedCrossRef
12.
Zurück zum Zitat Çakmak E, Ece A, Kelekçi S, Yolbaş İ, Güneş A, Şen V (2013) Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever. J Clin Exp Invest 4:213–218CrossRef Çakmak E, Ece A, Kelekçi S, Yolbaş İ, Güneş A, Şen V (2013) Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever. J Clin Exp Invest 4:213–218CrossRef
13.
Zurück zum Zitat Lachmann HJ, Sengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, Hawkins PN (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750CrossRef Lachmann HJ, Sengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, Hawkins PN (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750CrossRef
14.
Zurück zum Zitat Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Bassoy Y, Yilmaz E (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMed Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Bassoy Y, Yilmaz E (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMed
15.
Zurück zum Zitat Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112PubMedCrossRef Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112PubMedCrossRef
16.
Zurück zum Zitat Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A (2005) Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 35(1):57–64PubMedCrossRef Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A (2005) Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 35(1):57–64PubMedCrossRef
17.
Zurück zum Zitat Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A (2003) Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 30(2):308–312PubMed Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A (2003) Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 30(2):308–312PubMed
18.
Zurück zum Zitat Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155PubMedCrossRef Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155PubMedCrossRef
19.
Zurück zum Zitat Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, Shainberg B, Livneh A (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182–188PubMedCrossRef Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, Shainberg B, Livneh A (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182–188PubMedCrossRef
20.
Zurück zum Zitat Sarı I, Birlik M, Kaşifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheum 1:21–33CrossRef Sarı I, Birlik M, Kaşifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheum 1:21–33CrossRef
21.
Zurück zum Zitat Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 291(18):934–937PubMedCrossRef Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 291(18):934–937PubMedCrossRef
22.
Zurück zum Zitat Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005PubMedCrossRef Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005PubMedCrossRef
23.
Zurück zum Zitat Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, Pras M (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26(3):612–627PubMedCrossRef Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, Pras M (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26(3):612–627PubMedCrossRef
24.
Zurück zum Zitat Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, Pras M, Livneh A (2001) Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 102(3):272–276PubMedCrossRef Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, Pras M, Livneh A (2001) Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 102(3):272–276PubMedCrossRef
25.
Zurück zum Zitat Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977PubMedCrossRef Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977PubMedCrossRef
26.
Zurück zum Zitat Zemer D, Pras M, Sohar E, Gafni J (1976) Letter: Colchicine in familial Mediterranean fever. N Engl J Med 294(3):170–171PubMedCrossRef Zemer D, Pras M, Sohar E, Gafni J (1976) Letter: Colchicine in familial Mediterranean fever. N Engl J Med 294(3):170–171PubMedCrossRef
Metadaten
Titel
Risk factors for subclinical inflammation in children with Familial Mediterranean fever
verfasst von
Meral Torun Bayram
Tufan Çankaya
Elçin Bora
Salih Kavukçu
Ayfer Ülgenalp
Alper Soylu
Mehmet Türkmen
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 8/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3227-z

Weitere Artikel der Ausgabe 8/2015

Rheumatology International 8/2015 Zur Ausgabe

Letter to the Editor - Scientific Poetry

A sympathetic struggle

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.